Quantcast

Latest Oncothyreon Inc. Stories

2010-11-03 07:00:00

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chemotherapeutic agent docetaxel. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The primary objective of the Phase 1 dose-escalation portion of the trial is to determine the maximum...

2010-11-01 07:00:00

SEATTLE, Nov. 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its third quarter 2010 financial results and provide a review of its pipeline of products in development on Monday, November 8, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the...

2010-09-27 07:00:00

SEATTLE, WA, Sept. 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 5th Annual JMP Securities Healthcare Conference in New York on Tuesday, September 28, 2010, at 10:30 a.m. Eastern Time. A live and archived webcast of Dr. Kirkman's presentations will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon...

2010-09-24 07:50:00

SEATTLE, WA, Sept. 24 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY), announced it has entered into a securities purchase agreement in connection with a private placement. Upon the closing of the private placement, Oncothyreon will receive gross proceeds of approximately $14.9 million resulting from the sale of approximately 4.24 million units at a purchase price of $3.50 per unit. The purchase price per unit represents approximately a 7.2% discount to the 30-day trailing...

2010-08-31 07:00:00

SEATTLE, Aug. 31 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the appointment of Julie M. Eastland as Chief Financial Officer and Vice President, Corporate Development, effective September 7, 2010. Ms. Eastland's responsibilities will include financial management, investor relations and business development. "Ms. Eastland brings more than 25 years of financial management experience to Oncothyreon," said Robert L. Kirkman, M.D., President and CEO of Oncothyreon. "We...

2010-08-05 15:01:00

SEATTLE, Aug. 5 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss of $4.3 million or $0.17 per basic and diluted share for the quarter ended June 30, 2010, compared with a net loss of $6.3 million or $0.30 per basic and diluted share for the comparable period in 2009. Oncothyreon also reported a net loss of $5.1 million or $0.20 per basic and diluted share for the six months ended June 30, 2010, compared with a net loss of $8.8 million or $0.43 per basic and...

2010-07-26 07:00:00

SEATTLE, WA, July 26 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) will conduct a conference call to discuss its second quarter 2010 financial results on Thursday, August 5, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be accessed on the "Events" page of the "News & Events" section of Oncothyreon's...

2010-07-07 07:00:00

SEATTLE, WA, July 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it has secured a committed equity financing facility under which it may sell up to $20 million of its shares of common stock to Small Cap Biotech Value, Ltd. (the "investor") over a 24-month period. Oncothyreon is not obligated to use the facility and remains free to enter into and consummate other equity and debt financing transactions. Oncothyreon intends to use the proceeds from future sales...

2010-06-07 08:00:00

DESCRIBES PHASE 2 DEVELOPMENT PLANS FOR PX-866 SEATTLE, WA, June 7 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") announced that results from Phase 1 clinical trials of the Company's small molecule product candidates PX-866, an irreversible inhibitor of PI-3 kinase, and PX-478, an inhibitor of HIF-1 alpha, were presented today at the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, IL. In conjunction with the presentations, the Company...

2010-06-03 07:00:00

SEATTLE, WA, June 3 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June. Presentations include: - The Noble Financial Sixth Annual Equity Conference on Tuesday, June 8, 2010 at 10:30 a.m. Eastern Time in Hollywood, FL. - The 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010 at 11:20 a.m. Eastern Time...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related